Key result
Major periprocedural bleeding after TAVI links to ~28% mortality at one year.
Why the study?
Bleeding remains the most common complication following TAVI and carries a significant risk of mortality, making timely identification, prevention, and management essential.
This review highlights that while bleeding incidence after TAVI has declined, major bleeding still occurs in 2.0-6.6% of patients and carries high mortality, emphasizing the need for optimized antithrombotic therapy and access techniques.
High mortality after periprocedural bleeding in TAVI warrants ongoing caution; leaves open optimal antithrombotic and access strategies.
Bleeding remains the most common complication following transcatheter aortic valve implantation (TAVI), despite a decline in its incidence over time. Periprocedural (≤30 days) major or life-threatening bleeding is reported to occur in 2.0-6.6% of patients undergoing TAVI. Major bleeding events carry a significant risk of mortality, with rates of 14.1% at 30 days and 27.8% at one year. The timely identification and management of patients at an elevated risk are therefore essential. Preventive measures include optimizing antithrombotic therapies, utilizing ultrasound-guided femoral access, employing single arterial access or a radial artery for secondary access, and administering unfractionated heparin under close monitoring. Long-term follow-up is essential for recognizing and managing late hemorrhages. In this review, we aimed to provide an in-depth analysis of bleeding events associated with TAVI and the most recent updates regarding the antithrombotic therapy of TAVI patients and its clinical impact.
No takes yet. Share an insight, caveat, or question.
Xenogiannis et al. (2025) conducted a review in Bleeding events after transcatheter aortic valve implantation (TAVI). Antithrombotic therapy and preventive measures was evaluated. Periprocedural major or life-threatening bleeding after TAVI occurs in 2.0-6.6% of patients and is associated with significant mortality rates of 14.1% at 30 days and 27.8% at one year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: